Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Short Interest Update

Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 1,720,000 shares, an increase of 13.2% from the December 31st total of 1,520,000 shares. Currently, 5.2% of the company's shares are sold short. Based on an average daily trading volume, of 773,000 shares, the short-interest ratio is presently 2.2 days.

Hedge Funds Weigh In On Werewolf Therapeutics

Several large investors have recently modified their holdings of HOWL. SG Americas Securities LLC acquired a new position in Werewolf Therapeutics in the 3rd quarter valued at $29,000. Point72 DIFC Ltd acquired a new stake in Werewolf Therapeutics in the second quarter valued at about $34,000. XTX Topco Ltd bought a new stake in shares of Werewolf Therapeutics during the 3rd quarter valued at approximately $45,000. Levin Capital Strategies L.P. bought a new stake in shares of Werewolf Therapeutics during the fourth quarter worth $74,000. Finally, American Century Companies Inc. increased its holdings in Werewolf Therapeutics by 50.7% in the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company's stock worth $92,000 after purchasing an additional 12,656 shares in the last quarter. 64.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on the stock. JMP Securities lowered their target price on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a "market outperform" rating for the company in a research note on Tuesday, January 14th. HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research note on Tuesday, November 19th.

Werewolf Therapeutics Stock Performance

Shares of HOWL traded down $0.05 during mid-day trading on Thursday, reaching $1.36. The company's stock had a trading volume of 159,085 shares, compared to its average volume of 266,933. The business has a 50-day simple moving average of $1.54 and a two-hundred day simple moving average of $1.98. Werewolf Therapeutics has a 1-year low of $1.26 and a 1-year high of $8.19. The stock has a market cap of $60.60 million, a P/E ratio of -0.89 and a beta of 0.36. The company has a current ratio of 10.10, a quick ratio of 10.10 and a debt-to-equity ratio of 0.29.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.